ANSTO – Sodium Iodide [131I] Therapy Capsules (50 to 6000 MBq)

Product Information

Registration Status: Active

ANSTO - Sodium Iodide [131I] Therapy Capsules (50 to 6000 MBq) is approved to be sold in Singapore with effective from 2021-03-08. It is marketed by TRANSMEDIC PTE LTD, with the registration number of SIN16117P.

This product contains Sodium Iodide 50 to 6000 MBq/capsule in the form of CAPSULE. It is approved for ORAL use.

This product is manufactured by ANSTO in AUSTRALIA.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Sodium Iodide


Sodium iodide is a water-soluble ionic compound with a crystal lattice. Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine. Radiolabelled compound, [DB09293], is used as a diagnostic tool to evaluate thyroid function and morphology.


Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [L2065].


Iodide salts are readily absorbed in the gastrointestinal tract [L2061].
Iodides are distributed widely throughout extracellular fluid of thyroid gland [L2061].


Acute oral LD50 is 4340 mg/kg in rat and 1000 mg/kg in mouse [MSDS]. Chronic iodide overdoses may result in iodism, which is commonly characterized by salivation, coryza, sneezing, conjunctivitis, headache, fever, laryngitis, bronchitis, stomatitis, parotitis and oedema of the glottis [L2061]. Up to 10g of sodium iodide has been administered intravenously without any signs of toxicity [L2061].

Active Ingredient/Synonyms

Sodium iodide | Sodium iodide |

Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank